keyword
MENU ▼
Read by QxMD icon Read
search

treatment of hepatocellular carcinoma

keyword
https://www.readbyqxmd.com/read/28212535/integration-of-the-cancer-related-inflammatory-response-as-a-stratifying-biomarker-of-survival-in-hepatocellular-carcinoma-treated-with-sorafenib
#1
Jessica Howell, David J Pinato, Ramya Ramaswami, Tadaaki Arizumi, Carlotta Ferrari, Antonello Gibbin, Michela E Burlone, Giulia Guaschino, Pierluigi Toniutto, James Black, Laura Sellers, Masatoshi Kudo, Mario Pirisi, Rohini Sharma
BACKGROUND AND AIMS: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. RESULTS: 442 patients with advanced stage HCC on sorafenib were recruited (follow-up 5096 person-months at risk). 88% had BCLC stage B or greater HCC and 72.3% had Child-Pugh A cirrhosis. On Cox multivariate regression, previously-treated HCC (HR 0...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28211921/metronomic-capecitabine-versus-best-supportive-care-as-second-line-treatment-in-hepatocellular-carcinoma-a-retrospective-study
#2
Andrea Casadei Gardini, Flavia Foca, Mario Scartozzi, Nicola Silvestris, Emiliano Tamburini, Luca Faloppi, Oronzo Brunetti, Britt Rudnas, Salvatore Pisconti, Martina Valgiusti, Giorgia Marisi, Francesco Giuseppe Foschi, Giorgio Ercolani, Davide Tassinari, Stefano Cascinu, Giovanni Luca Frassineti
Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7-3.5). Median overall survival was 12...
February 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28211073/challenges-in-treatment-of-hepatitis-c-among-patients-with-hepatocellular-carcinoma
#3
Behnam Saberi, Alia S Dadabhai, Christine M Durand, Benjamin Philosophe, Andrew M Cameron, Mark S Sulkowski, Ahmet Gurakar
No abstract text is available yet for this article.
February 17, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28210201/therapeutic-effect-of-astragalus-polysaccharides-on-hepatocellular-carcinoma-h22-bearing-mice
#4
Xiaoyu Lai, Weibiao Xia, Jing Wei, Xinghong Ding
The purpose of this study was to investigate the effect of astragalus polysaccharides (APSs), active constituents of astragalus, in the treatment of hepatocellular carcinoma (HCC) and their potential as a promising candidate for future anticancer drug development. Astragalus polysaccharide was administered at different doses to HCC H22-bearing mice to investigate their antitumor effects. Results revealed that APS inhibited the growth of H22 cells with a tumor inhibition rate in the APS 400 mg·kg(-1) group of 59...
January 2017: Dose-response: a Publication of International Hormesis Society
https://www.readbyqxmd.com/read/28210086/prognostic-factors-associated-with-mortality-in-patients-with-gastric-fundal-variceal-bleeding
#5
Keishi Komori, Masaru Kubokawa, Eikichi Ihara, Kazuya Akahoshi, Kazuhiko Nakamura, Kenta Motomura, Akihide Masumoto
AIM: To determine the prognostic factors associated with mortality in patients with gastric fundal variceal (GFV) bleeding. METHODS: In total, 42 patients were endoscopically diagnosed with GFV bleeding from January 2000 to March 2014. We retrospectively reviewed the patients' medical records and assessed their history, etiology of liver cirrhosis, disease conditions, treatment options for GFV bleeding, medications administered before and after onset of GFV bleeding, blood test results (hemoglobin, albumin, and bilirubin concentrations), and imaging results (including computed tomography and abdominal ultrasonography)...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28209963/the-impact-of-esophagogastric-varices-on-the-prognosis-of-patients-with-hepatocellular-carcinoma
#6
Wei-Yao Hsieh, Ping-Hsien Chen, I-Yen Lin, Chien-Wei Su, Yee- Chao, Teh-Ia Huo, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin, Jaw-Ching Wu
Whether or not esophagogastric varices (EGV) could determine the outcomes of patients with hepatocellular carcinoma (HCC) is still unclear. A total of 990 treatment-naive HCC patients who received an esophagogastroduodenoscopy at the time of HCC diagnosis were retrospectively enrolled. The factors in terms of prognosis were analyzed by Cox proportional hazards model and propensity score matching analysis. Among the enrolled patients, 480 (48.5%) patients had EGV. Patients with EGV had a significantly lower cumulative 5-year survival rate than those without EGV (24...
February 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28209723/functional-metabolic-and-dynamic-mitochondrial-changes-in-the-rat-cirrhosis-hepatocellular-carcinoma-model-and-the-protective-effect-of-ifc-305
#7
Enrique Chavez, Maria Guadalupe Lozano-Rosas, Mariana Dominguez-Lopez, Gabriela Velasco-Loyden, Jesus Rafael Rodriguez-Aguilera, Concepcion Jose-Nunez, Marietta Tuena de Gomez-Puyou, Victoria Chagoya de Sanchez
BACKGROUND: Mitochondrion is an important metabolic and energetic organelle which regulates several cellular processes. Mitochondrial dysfunction has been related with liver diseases including hepatocellular carcinoma. As a result, the energetic demand is not properly supplied and mitochondrial morphologic changes has been observed resulting in an altered metabolism. We previously demonstrated the chemopreventive effect of the hepatoprotector IFC-305. AIM: In this work we aimed to evaluate the functional, metabolic, and dynamic mitochondrial alterations in the sequential model of cirrhosis-hepatocellular carcinoma induced by diethylnitrosamine in rats and the possible beneficial effect of IFC-305...
February 16, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28207681/significance-of-glypican-3-gpc3-expression-in-hepatocellular-cancer-diagnosis
#8
Bin Sun, Zhi Huang, Bi Wang, Yanglong Yu, Shihai Lin, Lei Luo, Yuzhu Wang, Zheng Huang
BACKGROUND Primary hepatocellular carcinoma (HCC) is a malignant tumor that is common China. Early diagnosis is of great significance for improving treatment efficiency. GPC3 level is closely related to HCC occurrence. This study investigated GPC3 expression in HCC patient serum and tissue, and assessed the significance of GPC3 combined AFP detection in HCC diagnosis. MATERIAL AND METHODS A total of 76 HCC patients in our hospital were enrolled. Immunohistochemistry was applied to test GPC3 expression in cancer tissue and para-carcinoma tissue...
February 16, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28205284/prognostic-impact-of-complications-after-resection-of-early-stage-hepatocellular-carcinoma
#9
Georgios Antonios Margonis, Kazunari Sasaki, Nikolaos Andreatos, Yujiro Nishioka, Toshitaka Sugawara, Neda Amini, Stefan Buettner, Masaji Hashimoto, Junichi Shindoh, Timothy M Pawlik
BACKGROUND: Resection is the most effective treatment for HCC. However, postoperative morbidity is common and its impact on long-term oncological outcome remains unclear. METHODS: Long-term outcomes of 774 patients who underwent curative resection for early stage HCC at Johns Hopkins Hospital and Toranomon Hospital were investigated after stratifying by the development of postoperative overall and infectious complications. RESULTS: A minor or major postoperative complication developed in 281 and 65 patients, respectively, while postoperative mortality was 1...
February 15, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28203135/successful-treatment-of-hepatocellular-carcinoma-complicated-by-fanconi-anemia
#10
Koji Takahashi, Eiichiro Suzuki, Masayuki Yokoyama, Masanori Inoue, Toru Wakamatsu, Tomoko Saito, Yuko Kusakabe, Sadahisa Ogasawara, Yoshihiko Ooka, Akinobu Tawada, Yuhei Nagao, Chiaki Nakaseko, Tetsuhiro Chiba
A 42-year-old woman with liver tumors was referred to our hospital. Her condition was complicated by Fanconi anemia, and she had undergone total laryngectomy 8 years ago. On admission, contrast-enhanced computed tomography revealed hypervascular tumors in the right hepatic lobe. Ultrasound-guided tumor biopsy revealed that the tumor comprised moderately differentiated hepatocellular carcinoma. Although the patient exhibited preserved liver function (Child-Pugh A), complete blood count revealed severe pancytopenia...
January 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/28202430/vespro-an-individual-patient-data-prospective-meta-analysis-of-selective-internal-radiation-therapy-versus-sorafenib-for-advanced-locally-advanced-or-recurrent-hepatocellular-carcinoma-of-the-sarah-and-sirvenib-trials
#11
Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce Kh Chow, Valérie Vilgrain
BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) has an overall poor prognosis. Currently there are 2 ongoing prospective randomized controlled trials that are evaluating the efficacy and safety of sorafenib and selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres in patients with advanced HCC. The SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma (SARAH; 459 patients) trial is being performed in Europe and the SIRt VErsus SorafeNIB (SIRveNIB; 360 patients) trial in the Asia Pacific region...
February 15, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28198177/innovative-molecular-targeted-agents-in-hepatocellular-carcinoma-new-gladiators-on-the-arena
#12
Jose Ferri, Yanina Dockx, Luisa Vonghia, Konstantinos Papadimitriou, Marika Rasschaert, Sven Francque, Marc Peeters, Christian Rolfo
Treatment of advanced hepatocellular carcinoma remains a challenge, with discouraging results in terms of survival. Following the approval of the multikinase inhibitor sorafenib, a large number of molecular targeted agents have been tested, but many have failed to demonstrate significant efficacy in clinical trials. However, the deeper knowledge in HCC pathogenesis achieved through the years has enabled us to explore new targetable pathways as well as biomarkers that could lead to treatment personalization...
February 14, 2017: Minerva Chirurgica
https://www.readbyqxmd.com/read/28198132/clinical-results-of-proton-beam-therapy-for-hepatocellular-carcinoma-over-5%C3%A2-cm
#13
Kanako Kimura, Tatsuya Nakamura, Takashi Ono, Yusuke Azami, Motohisa Suzuki, Hitoshi Wada, Kanako Takayama, Hiromasa Endo, Teruhito Takeyama, Katsumi Hirose, Yoshihiro Takai, Yasuhiro Kikuchi
PURPOSE: This study was conducted to evaluate the safety and efficacy of proton beam therapy for large hepatocellular carcinoma (HCC). METHODS: Twenty-four patients with a HCC larger than 5.0 cm were treated with proton beam therapy at our institution between 2008 and 2015. RESULTS: The clinical stage was I in 2 patients, II in 9 patients and IIIB in 13 patients. Ten of the 24 patients were not surgical candidates because of advanced HCC or old age...
February 14, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28197830/validation-of-the-risk-prediction-models-state-score-and-start-strategy-to-guide-tace-treatment-in-patients-with-hepatocellular-carcinoma
#14
Aline Mähringer-Kunz, Roman Kloeckner, Michael B Pitton, Christoph Düber, Irene Schmidtmann, Peter R Galle, Sandra Koch, Arndt Weinmann
PURPOSE: Several scoring systems that guide patients' treatment regimen for transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) have been introduced, but none have gained widespread acceptance in clinical practice. The purpose of this study is to externally validate the Selection for TrAnsarterial chemoembolization TrEatment (STATE)-score and START-strategy [i.e., sequential use of the STATE-score and Assessment for Retreatment with TACE (ART)-score]. MATERIALS AND METHODS: From January 2000 to September 2015, 933 patients with HCC underwent TACE at our institution...
February 14, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28197805/economic-analysis-and-budget-impact-of-tenofovir-and-entecavir-in-the-first-line-treatment-of-hepatitis-b-virus-in-italy
#15
M Ruggeri, M Basile, S Coretti, C Drago, A Cicchetti
BACKGROUND: Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications. The treatments of chronic hepatitis B cannot totally cure the disease but can prevent its progression to hepatocellular carcinoma, decreasing the levels of both morbidity and mortality. To date, there are several therapies indicated by the international guidelines as first-line treatments for the management of hepatitis B; two of the most effective are those based on either tenofovir or entecavir...
February 14, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28197682/intraperitoneal-metastases-after-transarterial-embolization-of-hepatocellular-carcinoma-an-observational-study
#16
Jeffrey M Meier, Spencer C Behr, Eric Jordan, K Pallav Kolli, Benjamin M Yeh
PURPOSE: Transarterial embolization is frequently used to treat local hepatocellular carcinoma (HCC). While various complications are known to occur following transarterial embolization, only one prior case of peritoneal spread of HCC occurring shortly after transarterial chemoembolization has been reported. We present five cases of peritoneal spread of HCC following transarterial embolization (including bland embolization, conventional transarterial chemoembolization (TACE), and doxorubicin-eluting beads TACE) and identify features common among those cases...
February 14, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28197637/inhibition-of-fasn-suppresses-migration-invasion-and-growth-in-hepatoma-carcinoma-cells-by-deregulating-the-hif-1%C3%AE-igfbp1-pathway
#17
Jiaojiao Gong, Shasha Shen, Yixuan Yang, Si Qin, Lifan Huang, Hongmin Zhang, Ling Chen, Yaqin Chen, Shiying Li, Sha She, Min Yang, Hong Ren, Huaidong Hu
Hepatocellular carcinoma is the second most common cause of cancer-related deaths worldwide. Due to a high propensity to metastasize, active angiogenesis and rapid proliferation, recurrence and poor prognosis are major obstacles for treatment and cure of this disease. However, the detailed mechanisms of how fatty acid synthase (FASN) promotes migration, invasion and healing in tumor cells remain unclear. In the present study, the previous results that FASN was expressed higher in cancer samples than in non-cancerous samples, and influenced migration, invasion of hepatoma carcinoma cells, were verified by immunohistochemistry, tissue microarrays, Transwell assay and wound healing assay...
February 2, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28196353/importance-of-screening-for-esophagogastric-varices-in-na%C3%A3-ve-hepatocellular-carcinoma-patients-within-milan-criteria-indicator-for-liver-transplantation
#18
Takamasa Kawakami, Atsushi Hiraoka, Kojiro Michitaka, Tomoyuki Ninomiya, Masashi Hirooka, Yoichi Hiasa
BACKGROUND/AIMS: Patients with hepatocellular carcinoma (HCC) beyond Milan criteria (MC) are not eligible for liver transplantation (LT). To elucidate prognostic factors significantly linked to recurrence beyond MC or death related to the liver, we evaluated the clinical features in a series of HCC patients within MC at baseline. METHODS: We enrolled 255 naïve HCC patients (≤70 years) within the MC who underwent upper-gastrointestinal-endoscopy, and were treated with resection or radiofrequency ablation (62 years old [median]; male:female = 202:53; Child-Pugh A:B = 216:39)...
February 15, 2017: Digestive Surgery
https://www.readbyqxmd.com/read/28196303/the-long-noncoding-rna-schlah-suppresses-metastasis-of-hepatocellular-carcinoma-through-interacting-with-fus
#19
Zhouhong Ge, Zhuoan Cheng, Xinrong Yang, Xisong Huo, Ning Wang, Hui Wang, Cun Wang, Dishui Gu, Fangyu Zhao, Ming Yao, Jia Fan, Wenxin Qin
Emerging evidence has indicated that deregulation of long non-coding RNAs (lncRNAs) can contribute to the progression and metastasis of human cancer, including hepatocellular carcinoma (HCC). However, the roles of most lncRNAs in HCC remain largely unknown. Here we found a long noncoding RNA termed SchLAH (seven chromosome locus associated with HCC; also called BC035072) was generally downregulated in HCC. Low expression of SchLAH was significantly correlated with shorter overall survival of HCC patients. In vitro and in vivo assays indicated that overexpression of SchLAH inhibited the migration and lung metastasis of HCC cells...
February 14, 2017: Cancer Science
https://www.readbyqxmd.com/read/28195873/niace-score-for-hepatocellular-carcinoma-patients-treated-by-surgery-or-transarterial-chemoembolization
#20
Xavier Adhoute, Guillaume Pénaranda, Jean Luc Raoul, Emilie Bollon, Bernard Pol, Yves P Letreut, Hervé Perrier, Olivier Bayle, Olivier Monnet, Patrick Beaurain, Cyril Muller, Jean Hardwigsen, Gaëlle Lefolgoc, Paul Castellani, Jean P Bronowicki, Marc Bourlière
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) prognostic scores could be useful in addition to the Barcelona Clinic Liver Cancer (BCLC) system to clarify patient prognosis and guide treatment decision. The NIACE (tumor Nodularity, Infiltrative nature of the tumor, serum Alpha-fetoprotein level, Child-Pugh stage, ECOG performance status) score distinguishes different prognosis groups among BCLC A, B, and C HCC patients. Our aims are to evaluate the NIACE score and its additive value in two HCC cohorts treated either by surgery or by chemoembolization, and then according to the BCLC recommendations...
February 13, 2017: European Journal of Gastroenterology & Hepatology
keyword
keyword
40124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"